611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
New, Natural Pesticides Effective Against Mosquitoes: StudyDoctors Not Talking About Newer Meningitis VaccineAHA: 'Bad' Cholesterol Can Be Deadly in Otherwise Healthy PeopleHealth Tip: Keep Your Bladder Healthier4 Ways to Protect Your Child From Allergic Reactions at SchoolFDA Approves 1st Generic EpiPenThinning Retina Seen as Early Warning Sign for Parkinson'sSleep in Your Contacts, Risk Serious Eye Damage: CDCAHA: Wildfire Smoke Threatens Health of Those Near and FarStem Cells Restore Some Vision in Blind MiceHealth Tip: Are You at Risk for Macular Degeneration?Dialysis Linked to Dementia in SeniorsGene Test Predicts Risk of 5 Common DiseasesStudy Hints at Why Women Suffer More Migraines Than MenHealth Tip: Making an Emergency CallHealth Tip: Identify Bug BitesHealth Tip: Most Americans are OverweightA Weak Grip May Signal Future Health Trouble -- Even in KidsEye Disease Link to Alzheimer's SeenNew Research Suggests Glaucoma May Be an Autoimmune DiseaseHealth Tip: Fight Frequent FatigueEarly Onset Type 1 Diabetes Linked to Heart Disease, Shorter LifeAHA: Obesity May Increase Risk for Peripheral Artery DiseaseHealth Tip: Getting a Second Opinion Before SurgeryHealth Tip: Avoid Mosquito BitesPreschoolers' Parents May Be Unprepared to Treat AsthmaSchool Prep Includes Planning Allergy, Asthma ManagementHave Glaucoma and Need to Switch Eye Docs? Here's What You Need to DoHealth Woes Hit 1 in 7 Babies Exposed to Zika in U.S. TerritoriesStudy Urges Genetic Testing of Relatives of Aortic Disease PatientsHepatitis-Infected Kidneys a Safe Option for Transplant: StudySigns Your Child Might Have Hearing LossHow to Keep Foodborne Illness at BayAHA: Air Pollution Exposure Linked to Enlarged HeartsScientists Trace Link Between Head Injuries and Parkinson'sScans Help Spot Heart Trouble Early in People With LupusHealth Tip: Warmer Weather Triggers RashesToo Many Kidney Disease Patients in the Dark About DietGerms Gaining Resistance to Hand Gels in HospitalsHealth Tip: Recognize Signs of a Urinary Tract InfectionMore Research Links Sunscreens to Marine-life DamageLyme Disease Striking More Americans in More StatesClimate Change Means More Deadly Heat Waves: StudyObesity Warps the Shape, Function of Young HeartsHere's What Happened When 1 Unvaccinated NYC Kid Got MeaslesGyms With Tanning Beds Send Mixed MessageSummers Less Smoggy Now, But Winter Air Hasn't ImprovedIt's Hot Outside: How to Stay Safe When Thermometers Rise3-Pronged Approach to Cancer PreventionCould Psoriasis Patients Eat Their Way to Fewer Symptoms?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures


HealthDay News
Updated: May 21st 2018

new article illustration

MONDAY, May 21, 2018 (HealthDay News) -- Doptelet (avatrombopag) has been approved by the U.S. Food and Drug Administration to treat adults with chronic liver disease who are slated to have a medical or dental procedure.

Doptelet was evaluated in a pair of clinical studies involving a total of 435 people with chronic liver disease and severe thrombocytopenia. The results showed that, compared to those treated with placebo, a higher proportion of patients treated with Doptelet had increased platelet counts and did not require platelet transfusion or any rescue therapy on the day of the procedure and up to seven days following the procedure.

The most common side effects included fever, abdominal pain, nausea, headache, fatigue, and swelling of the hands or feet. An elevated risk of blood-clot formation was a less common but more serious adverse reaction, the FDA said.

"Patients with chronic liver disease who have low platelet counts and require a procedure are at increased risk of bleeding," Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "Doptelet was demonstrated to safely increase the platelet count. This drug may decrease or eliminate the need for platelet transfusions, which are associated with risk of infection and other adverse reactions."

The drug is produced by the Japanese pharma firm AkaRx.

More Information